Interactive Features

Test Your Knowledge

Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?

06/22/2020

True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.

True or False: MDMs in plasma...

06/22/2020

Oncology

Test Your Knowledge

Quiz: Should Pembrolizumab Be New Standard of Care for MSI-H/dMMR Metastatic CRC?

06/04/2020

True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?

True or False: Pembrolizumab...

06/04/2020

Oncology

Test Your Knowledge

Quiz: Improved PFS with TAS-102 plus Bevacizumab Versus Monotherapy for mCRC?

05/22/2020

True or false: TAS-102 plus bevacizumab yields clinically significant PFS improvement over TAS-102 monotherapy in patients with metastatic colorectal cancer.

True or false: TAS-102 plus...

05/22/2020

Oncology

Test Your Knowledge

Quiz: Which Therapy is Preferred for mCRC After Progression?

05/04/2020

True or false: Upfront FOLFOXIRI plus bevacizumab reintroduced after progression is preferable to chemotherapy doublets for metastatic colorectal cancer.

True or false: Upfront FOLFOXIRI...

05/04/2020

Oncology

Test Your Knowledge

Quiz: Adding Sporadic Oxaliplatin to This Regimen Promising for CRC

04/02/2020

Combining which chemotherapy regimen with intermittent oxaliplatin could be as effective as adjuvant chemo postsurgery for colon cancer?

Combining which chemotherapy...

04/02/2020

Oncology

Test Your Knowledge

Quiz: Any Benefit to Continuing Full Induction Regimen in Metastatic CRC?

01/17/2020

True or False: There is no benefit to continuing a full induction regimen until progression without a period of observation or maintenance therapy in patients with metastatic colorectal cancer.

True or False: There is no...

01/17/2020

Oncology

Test Your Knowledge

Quiz: Can We Predict Benefit of Preoperative Therapy for Sigmoid Colon Cancer?

01/03/2020

True or False: CT scans may predict whether patients with sigmoid colon cancer will benefit from preoperative therapy.

True or False: CT scans may...

01/03/2020

Oncology

Test Your Knowledge

Quiz: Is 3-Month Capecitabine Plus Oxaliplatin Appropriate for CRC?

10/28/2019

True or False: For patients with CRC, a 3-month chemo regimen of capecitabine plus oxaliplatin may be the most appropriate treatment option, especially among those with low-risk disease.

True or False: For patients with...

10/28/2019

Oncology

Test Your Knowledge

Quiz: Adding Aflibercept to Modified FOLFOX6 in High-Risk Rectal Cancer

09/24/2019

True or False: Adding aflibercept to a modified FOLFOX6 induction regimen helps increase the rate of pathologic complete response in patients with high-risk rectal cancer without considerably increasing surgical complications.

True or False: Adding...

09/24/2019

Oncology

Test Your Knowledge

Quiz: Does Physical Activity Lower PFS in Metastatic CRC?

09/03/2019

True or False: In a study of patients with metastatic CRC, physical activity was associated with a shorter PFS and higher risk for treatment-related adverse events.

True or False: In a study of...

09/03/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology